Showing 771-780 of 5127 results for "".
- Study: Dupilumab Shows Long-Term Disease Control in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/study-dupilumab-shows-long-term-disease-control-in-pediatric-atopic-dermatitis/2487681/Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- ESCD 2026: New Data Show Ongoing Burden of Chronic Hand Eczemahttps://practicaldermatology.com/news/escd-2026-new-data-on-chronic-hand-eczema-burden-and-unmet-needs/2487581/LEO Pharma will present new data at the European Society of Contact Dermatitis (ESCD) Congress 2026 in Copenhagen highlighting the significant burden chronic hand eczema (CHE) continues to place on patients across different stages of life, according to a press release from the manufacturer. The p
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Analysis Shows Long-Term Cost Impact of Psoriasis and Psoriatic Arthritishttps://practicaldermatology.com/news/analysis-highlights-long-term-cost-impact-of-psoriasis-and-psoriatic-arthritis/2487486/New research published in Dermatology and Therapy suggests the economic burden associated with psoriasis and psoriatic arthritis extends far beyond the diseases themselves and may reach hundreds of billions of dollars over a lifetime. Psoriatic Disease Comorbidities Drive Signifi
- Study Links Childhood Adversity to Mitochondrial Changes and Atopic Dermatitis Riskhttps://practicaldermatology.com/news/study-links-childhood-adversity-to-mitochondrial-changes-and-atopic-dermatitis-risk/2487465/A new study published in Psychoneuroendocrinology suggests that adverse childhood experiences (ACEs) may contribute to biologic changes associated with atopic disease, identifying mitochondrial DNA copy number (mtDNAcn) as a
- Oral Nicotinamide Linked to Fewer Skin Cancers and Lower Treatment Costshttps://practicaldermatology.com/news/oral-nicotinamide-linked-to-fewer-skin-cancers-and-lower-treatment-costs/2487444/Oral nicotinamide may offer a cost-effective strategy for preventing keratinocyte carcinoma (KC) in patients at high risk for developing multiple skin cancers, according to a new economic evaluation conducted within the Veterans Health Administration (VHA) published in JAMA Dermatology.<
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- FDA Adds Bemotrizinol to OTC Sunscreen Monograph in First New UV Filter in Over 20 Yearshttps://practicaldermatology.com/news/fda-adds-bemotrizinol-to-otc-sunscreen-monograph-in-first-new-uv-filter-in-over-20-years/2487644/The US Food and Drug Administration (FDA) has finalized an administrative order adding bemotrizinol as a permitted active ingredient in over-the-counter (OTC) sunscreen products, marking the first addition of a new sunscreen active ingredient to the OTC sunscreen m